UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,478	05/16/2007	Steinar Pedersen	2006_1432A	1393
	7590 10/06/200 , LIND & PONACK, I	EXAMINER		
2033 K STREET N. W. SUITE 800 WASHINGTON, DC 20006-1021			CHEUNG, WILLIAM K	
			ART UNIT	PAPER NUMBER
		1796		
			MAIL DATE	DELIVERY MODE
			10/06/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Office Action Commence	10/593,478	PEDERSEN ET AL.					
Office Action Summary	Examiner	Art Unit					
	WILLIAM K. CHEUNG	1796					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim 11 apply and will expire SIX (6) MONTHS from 12 cause the application to become ABANDONEI	Lely filed the mailing date of this communication. (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 24 Ja	nuary 2008.						
· <u> </u>	<u> </u>						
3) Since this application is in condition for allowan		secution as to the merits is					
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>6-9</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>6-9</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or	election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examiner	۲.						
10) The drawing(s) filed on is/are: a) acce		Examiner.					
Applicant may not request that any objection to the							
Replacement drawing sheet(s) including the correcti	*	* *					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
 Certified copies of the priority documents 							
Certified copies of the priority documents							
3. Copies of the certified copies of the prior	ity documents have been receive	ed in this National Stage					
application from the International Bureau	(PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date 5) Notice of Informal Patent Application							
Paper No(s)/Mail Date <u>092006</u> . 6) Other:							

DETAILED ACTION

1. In view of the amendment filed September 20, 2006, Claims 1-5 have been cancelled. Claims 6-9 are pending.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States
- 3. Claims 6, 8, 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Kasai et al. (US 4,694,035).
 - 6. (New) A method for production of storage stable polymer-oligomer particles with a high swelling capacity where polymer particles at first are added an initiator that is swelled into said particles and subsequently a monomer, or a mixture containing monomer, is added that is swelled into said particles, wherein the mole ratio between said initiator and said monomer is in the range from 0.07:1 to 0.01:1.

Kasai et al. (col. 2, line 26-31) disclose swellable particles that can swell 100:1 ratio. In example 9, Kasai et al. (col. 18, Example 9; col. 31, claim 1) disclose monodisperse polymethyl methacrylate particles used as seed particles swollen with monomer and initiators. According to the table of Example 9, 2 weight percent of

Page 3

Art Unit: 1796

benzoyl peroxide (initiator) based on the weight of monomer is used. Regarding claim 9, Kasai et al. (example 9) also indicate that the monomers added are in droplet forms. Since the molecular weights of the initiator and monomer are about the same, the disclosed 2 parts is equivalent to about 2 mole percent as claimed. Kasai et al. contain all the features as claimed. Claims 6, 8, 9 are anticipated.

EXAMPLE 9, AND COMPARATIVE EXAMPLE 6

	2-Ethylhexyl acrylate (water solubility: 1 × 10 ⁻⁴ g/100 g H ₂ O)	100	parts
15	Water	200	parts
	Sodium dodecylbenzenesulfonate	1.0	part
	Benzoyl peroxide (dissolved in 2-ethyl- hexyl scrylate)	2	parts

The above ingredients were stirred in the same manner as in Example 1 to prepare a dispersion in which 2-ethylhexyl acrylate was finely dispersed (maximum particle diameter: 0.09 µm). After allowing to stand for 3 hours, the above dispersion was measured for the number average particle diameter in a semi-stable condition, Dm, by the use of a dynamic light-scattering analyzer (Model N4 manufactured by Callter Co.). Dm was 9.32 µm.

The same 2-ethylhexyl acrylate dispersion as prepared above was used as a monomer dispersion, and monodisperse polymethyl methacrylate particles (number average particle diameter: 0.12 µm) were used as seed particles. The amount (solids) of polymethyl methacrylate particles used, the desired number average particle diameter D, and the contact time between 2ethylhexyl acrylate droplets and seed particles were determined as shown in Table 3. Application/Control Number: 10/593,478 Page 4

Art Unit: 1796

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 5. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kasai et al. (US 4,694,035).

Set forth from paragraph 3 of instant office action, the invention of claim 7 is very similar to the method as taught in Kasai et al.

The difference between the invention of claim 7 and Kasai et al. is that Kasai et al. disclose the use of 2 parts of initiator instead of from 3 to 6 mole percent as claimed.

However, since Kasai et al. have taught a process embodiment that is very similar to the process as claimed, the mere difference or a slight change in concentration would be considered obvious in view of MPEP 2144.05. Motivated by the expectation of success of that the initiator concentration can be varied to optimize that properties of the polymer product produced.

Art Unit: 1796

II. OPTIMIZATION OF RANGES

A. Optimization Within Prior Art Conditions or Through Routine Experimentation

Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to WILLIAM K. CHEUNG whose telephone number is (571)272-1097. The examiner can normally be reached on Monday-Friday 9:00AM to 2:00PM; 4:00PM to 8:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David WU can be reached on (571) 272-1114. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/593,478 Page 6

Art Unit: 1796

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/William K Cheung/ Primary Examiner, Art Unit 1796

William K. Cheung, Ph. D. Primary Examiner September 30, 2008